Allarta Life Science is a regenerative medicine company that has developed a proprietary platform technology aimed at delivering allogeneic cell therapies while addressing significant challenges such as immune rejection and cell escape. With over 30 years of foundational expertise, the company focuses on creating safe and effective cell and stem cell therapies, with its lead product targeting type 1 diabetes (T1D). The platform utilizes innovative synthetic hydrogels that provide immune protection for transplanted beta cells, allowing for a metabolic connection while safeguarding these cells from the host's immune system. This approach is particularly significant as it aims to eliminate the need for systemic immune suppression, which is a major barrier in the application of islet cell therapies for T1D.

The technology developed by Allarta is positioned to advance the field of cell-based therapies, particularly in the context of T1D, where current treatment options often require chronic immunosuppression. The company is actively engaged in pre-clinical studies using porcine models to test the efficacy of its hydrogel platform with both islet and stem cell-derived beta cells. By focusing on enhancing the durability of these therapies and reducing the reliance on immunosuppressive drugs, Allarta aims to provide a functional cure for T1D, thereby addressing a critical need in the management of this autoimmune condition.

Canada

Built on 30+ years of foundational expertise, Allarta’s proprietary platform is designed to overcome immune rejection, prevent cell escape and safely deliver cell and stem cell therapies.
Our lead product is a cell therapy focused on type 1 diabetes (T1D) as a first indication.

Allarta Life Science

Company Details